Specifically, while some CRC patients with MMR-defects and considered to be MSI high do not seem to derive benefit from adjuvant 5-FU-based chemotherapy, they actually exhibit increased survival, rather than the decreased survival observed for RPL22L1 high patients [23, 32–34]. This evidence concerns the gene RPL22L1 and colorectal carcinoma.